2023
Delirium in older adults after percutaneous coronary intervention: Prevalence, risks, and clinical phenotypes
Park D, Jamil Y, Hu J, Lowenstern A, Frampton J, Abdullah A, Damluji A, Ahmad Y, Soufer R, Nanna M. Delirium in older adults after percutaneous coronary intervention: Prevalence, risks, and clinical phenotypes. Cardiovascular Revascularization Medicine 2023, 57: 60-67. PMID: 37414611, PMCID: PMC10730763, DOI: 10.1016/j.carrev.2023.06.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedDeliriumHospital MortalityHumansPercutaneous Coronary InterventionPhenotypePrevalenceRetrospective StudiesRisk FactorsTreatment OutcomeConceptsPercutaneous coronary interventionHospital mortalityHigher oddsOlder adultsHospital deliriumCoronary interventionAdverse health-related outcomesInpatient percutaneous coronary interventionNon-home dischargePeri-procedural settingAcute kidney injuryImpact of deliriumPost-procedural complicationsNational Inpatient SampleHealth-related outcomesDelirium preventionHospital complicationsMore comorbiditiesGastrointestinal hemorrhageKidney injuryAdverse eventsSecondary outcomesBlood transfusionPrimary outcomeIntracranial hemorrhageUse of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice
Nanna M, Kolkailah A, Page C, Peterson E, Navar A. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice. JAMA Cardiology 2023, 8: 89-95. PMID: 36322056, PMCID: PMC9631221, DOI: 10.1001/jamacardio.2022.3839.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1 RAsAtherosclerotic cardiovascular diseaseUse of SGLT2iPeptide-1 receptor agonistsCotransporter 2 inhibitorsHealth care systemKidney diseaseReceptor agonistCardiovascular diseaseGlucagonlike Peptide-1 Receptor AgonistsStage 5 chronic kidney diseaseEnd-stage kidney diseaseOutpatient health care utilizationDipeptidyl peptidase-4 inhibitorsCare systemQuarter of personsSecondary prevention medicationsGlucose-lowering medicationsRetrospective cohort studyChronic kidney diseasePeptidase-4 inhibitorsElectronic health record dataHealth care utilizationRecent national guidelines
2022
Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease
Nanna M, Nelson A, Haynes K, Shambhu S, Eapen Z, Cziraky M, Calvert S, Pagidipati N, Granger C. Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease. Journal Of The American Geriatrics Society 2022, 71: 1243-1249. PMID: 36538393, PMCID: PMC10089944, DOI: 10.1111/jgs.18172.Peer-Reviewed Original ResearchConceptsHigh-intensity statinsLipid-lowering therapyModerate-intensity statinsU.S. older adultsOlder adultsPCSK9 inhibitorsNon-statin lipid-lowering therapyMulticenter retrospective cohort studyRetrospective cohort studyMinority of patientsAtherosclerotic cardiovascular diseaseCoronary artery diseaseEligible older adultsCohort studyOlder patientsOverall cohortArtery diseaseIntensive treatmentCardiovascular diseaseASCVDSecondary measuresStatinsUntreated individualsPatientsTherapyHigh-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.
Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, Calvert SB, Gallagher K, Pagidipati NJ, Granger CB. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. Journal Of The American College Of Cardiology 2022, 79: 1802-1813. PMID: 35512860, PMCID: PMC9344279, DOI: 10.1016/j.jacc.2022.02.048.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseHigh-intensity statinsStatin useYounger patientsFemale patientsHigh-intensity statin useHigher Charlson comorbidity scoreAppropriate statin useNew guideline recommendationsCharlson comorbidity scoreRetrospective cohort studyPeripheral artery diseaseModerate-intensity statinsMultivariable logistic regressionCommercial health plansMedical claims dataComorbidity scoreIndex dateCohort studyOlder patientsPreventive therapyStatin usersArtery diseaseContemporary cohortGuideline recommendationsFrailty and outcomes following revascularization of lower-extremity peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)
Al-Damluji MS, Smolderen KG, Meng C, Dai F, Nanna MG, Sumpio B, Henke P, Mena-Hurtado C. Frailty and outcomes following revascularization of lower-extremity peripheral artery disease: Insights from the Vascular Quality Initiative (VQI). Vascular Medicine 2022, 27: 251-257. PMID: 35485400, DOI: 10.1177/1358863x221083701.Peer-Reviewed Original ResearchConceptsRisk Analysis IndexVascular Quality InitiativeLower extremity revascularizationFrailty screening toolsMFI-5Lower extremity peripheral artery diseaseScreening toolFrailty detectionAddition of frailtyPAD risk factorsPeripheral artery diseasePAD populationRevascularization typeVascular cohortMajor amputationPerioperative outcomesArtery diseaseFrailty indexFrailty toolsAdjusted analysisUnplanned amputationRisk factorsHigher oddsPredictive valuePatients
2020
Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults
Zeitouni M, Nanna MG, Sun JL, Chiswell K, Peterson ED, Navar AM. Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. Journal Of The American College Of Cardiology 2020, 76: 653-664. PMID: 32762899, PMCID: PMC7444655, DOI: 10.1016/j.jacc.2020.06.030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedCohort StudiesFemaleHumansMaleMiddle AgedMyocardial InfarctionPractice Guidelines as TopicRetrospective StudiesConceptsLipid-lowering therapyYears of agePremature myocardial infarctionIntensive lipid-lowering therapyHigh-risk criteriaMyocardial infarctionYoung adultsYounger patientsHigh low-density lipoprotein cholesterolAHA/ACC guidelinesMajor adverse cardiovascular eventsLow-density lipoprotein cholesterolDuke University Medical CenterACC/AHAAdverse cardiovascular eventsRecurrent myocardial infarctionMost young patientsReductase inhibitor therapyFirst myocardial infarctionAmerican Heart AssociationUniversity Medical CenterOlder age groupsCause deathCholesterol guidelinesStatin candidates